GlobeNewswire Inc.··X4 Pharmaceuticals, Inc.EMA Committee Backs Mavorixafor for WHIM Syndrome, First European Therapy
EMA committee endorses mavorixafor (XOLREMDI) for WHIM syndrome treatment, marking first approved therapy in Europe. Final Commission approval expected Q2 2026.
XFORWHIM syndromemavorixafor